UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 160 filers reported holding UNIQURE NV in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,617,191 | -36.4% | 241,012 | +8.6% | 0.00% | -100.0% |
| Q2 2023 | $2,544,429 | -42.3% | 222,027 | +1.4% | 0.00% | 0.0% |
| Q1 2023 | $4,411,062 | -11.4% | 219,020 | -0.2% | 0.00% | -50.0% |
| Q4 2022 | $4,977,402 | +25.0% | 219,559 | +3.4% | 0.00% | +100.0% |
| Q3 2022 | $3,982,000 | +18.9% | 212,253 | +18.2% | 0.00% | 0.0% |
| Q2 2022 | $3,348,000 | +2.0% | 179,567 | -1.2% | 0.00% | 0.0% |
| Q1 2022 | $3,283,000 | -10.7% | 181,676 | +2.5% | 0.00% | 0.0% |
| Q4 2021 | $3,676,000 | -34.4% | 177,202 | +1.2% | 0.00% | -50.0% |
| Q3 2021 | $5,606,000 | -0.5% | 175,138 | -4.2% | 0.00% | 0.0% |
| Q2 2021 | $5,632,000 | -5.2% | 182,853 | +3.7% | 0.00% | 0.0% |
| Q1 2021 | $5,942,000 | -2.6% | 176,365 | +4.5% | 0.00% | 0.0% |
| Q4 2020 | $6,099,000 | -0.6% | 168,791 | +1.4% | 0.00% | -33.3% |
| Q3 2020 | $6,133,000 | – | 166,512 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |